Updated: AbbVie to acquire ImmunoGen for $10B in banner year for ADCs
AbbVie plans to acquire ImmunoGen for $10.1 billion, the companies said Thursday morning, in a deal that would expand the Big Pharma’s presence in the oncology field and mark an exit for the 42-year-old Boston biotech.
The Chicago-area company will pay $31.26 per share in cash to get its hands on ImmunoGen’s oncology pipeline, which includes Elahere, the antibody-drug conjugate that’s approved for certain ovarian cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.